Comparative Pharmacology
Head-to-head clinical analysis: AURLUMYN versus FOLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURLUMYN versus FOLEX.
AURLUMYN vs FOLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Methotrexate, the active ingredient in FOLEX, is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with thymidylate and purine synthesis, leading to inhibition of DNA replication and cell proliferation.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
30 mg/m2 intravenously once weekly for 2 weeks followed by a 1-week rest period, or 5-10 mg/m2 intramuscularly or intravenously every 3-4 weeks. For rheumatoid arthritis, 7.5-15 mg orally once weekly.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life: 3-10 hours (mean ~5 hours) for low-dose regimens; higher doses or renal impairment may prolong half-life up to 24 hours.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Primarily renal excretion of unchanged drug: ~80-90% within 24 hours. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent